pharm edaily

[Shin-Min Joon, Edaily Reporter] Chairman Yoon Sung-tae of Huons Group returns to the front lines of management to lead the group’s great leap forward, which is celebrating its 60th anniversary this year.

On the morning of the 28th, Huons Global‘s annual general meeting of shareholders was held at the HuonsGlobal building in Pangyo, Seongnam. (Image=Huons)

Huons Global Co. Ltd. (Huons Global), the holding company of the Huons Group concluded the 38th annual general meeting of shareholders and board meeting on March 28th at the HuonsGlobal headquarter in Pangyo, Seongnam, during which all agenda items were approved.

Agenda items of this annual general meeting of shareholders included approval of financial statements of the 38th term and cash dividends of 250 Korean won per share, amendment to the articles of incorporation, reduction of capital reserves appointment of one inside and one outside directors (Song Soo young and Han Seung beom, respectively) appointment of outside director Lee Kyu-yeon as an audit committee member appointment of Han Seung beom as an audit committee member and remuneration cap for directors. All agendas were ratified by shareholders.

At the board meeting that followed the annual general meeting of shareholders, Chairman Yoon Sung-tae was appointed as Huons Global’s CEO. Huons Global now has co-CEOs Yoon Sung-tae and Song Soo young.

It has been three years since Chairman Yoon stepped down from the front lines of management by resigning from the role as the CEO of Huons Global in 2022. Chairman Yoon will now lead the group’s future business by assuming the role as the CEO at Huons Global, the holding company of Huons Group.

In particular he plans to focus on overcoming the economic crisis, fostering the group’s future core competences, expanding into global market, and securing competitive new drug candidates (pipelines) to spur the group’s leap forward.

Chairman of Huons Group Yoon said “Despite the ongoing internal and external uncertainties, 2025 will be the year for Huons Group to make a great leap forward, also celebrating its 60th anniversary this year. I plan to look into the group’s key tasks for future sustainable growth, such as expanding into the global market and securing new growth engines through research and development.”

Huons Global has implemented a shareholder return policy to increase the shareholder value. In 2023, the Company have announced mid and long term cash dividend policy. The companies are currently implementing plans to increase cash dividends per share by a minimum of 0% and a maximum of 30% compared to the previous fiscal year over a three year period (from 2023 to 2025) as well as a twice a year cash dividend plan of interim and year-end dividend.

In 2024 Huons Global achieved the highest sales ever since its foundation based on its consolidated financial statements. The Company recorded sales of 813.5 billion Korean won and operating profit of 97 billion Korean won in 2024, up 7.3%, -14.9% year on year, respectively.

A Huons Group’s official said “Huons Group has laid the foundation for continued and strong business growth for the past 60 years and it cannot be achieved without supportive shareholders and hard working employees. Huons Global will make every effort to present the future vision of Huons Group and support the growth of each business company through enhancing the brand value of the Huons Group by diversifying its business areas and portfolio.”

he added “The company will continue to strive to create sustainable value through strengthening business competitiveness, shareholder-friendly and socially responsible management.”

Huons Group has five KOSDAQ listed companies, including Huons Global (the holding company), Huons, Humedix, HuM&C, and Pangen Biotech, along with nine other subsidiaries and affiliates. Pangen Biotech, a biopharmaceutical company, was incorporated as a Huons’ affiliated company in December 2024.